Ocuphire Pharma Total Long Term Liabilities 2010-2024 | IRD
Ocuphire Pharma total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Ocuphire Pharma Annual Total Long Term Liabilities (Millions of US $) |
2023 |
$ |
2022 |
$ |
2021 |
$ |
2020 |
$28 |
2019 |
$ |
2018 |
$2 |
2017 |
$8 |
2016 |
$2 |
2015 |
$3 |
2014 |
$4 |
2013 |
$6 |
2012 |
$5 |
2011 |
$2 |
2010 |
$4 |
2009 |
$4 |
Ocuphire Pharma Quarterly Total Long Term Liabilities (Millions of US $) |
2024-06-30 |
|
2024-03-31 |
|
2023-12-31 |
|
2023-09-30 |
|
2023-06-30 |
|
2023-03-31 |
|
2022-12-31 |
|
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
$28 |
2020-09-30 |
$0 |
2020-06-30 |
$0 |
2020-03-31 |
$0 |
2019-12-31 |
|
2019-09-30 |
$0 |
2019-06-30 |
$1 |
2019-03-31 |
$1 |
2018-12-31 |
$2 |
2018-09-30 |
$4 |
2018-06-30 |
$3 |
2018-03-31 |
$5 |
2017-12-31 |
$8 |
2017-09-30 |
$7 |
2017-06-30 |
$10 |
2017-03-31 |
$17 |
2016-12-31 |
$2 |
2016-09-30 |
$4 |
2016-06-30 |
$3 |
2016-03-31 |
$5 |
2015-12-31 |
$3 |
2015-09-30 |
$2 |
2015-06-30 |
$3 |
2015-03-31 |
$4 |
2014-12-31 |
$4 |
2014-09-30 |
$6 |
2014-06-30 |
$7 |
2014-03-31 |
$12 |
2013-12-31 |
$6 |
2013-09-30 |
$5 |
2013-06-30 |
$5 |
2013-03-31 |
$4 |
2012-12-31 |
$5 |
2012-09-30 |
$2 |
2012-06-30 |
$1 |
2012-03-31 |
$2 |
2011-12-31 |
$2 |
2011-09-30 |
$5 |
2011-06-30 |
$7 |
2011-03-31 |
$7 |
2010-12-31 |
$4 |
2010-09-30 |
$1 |
2010-06-30 |
$1 |
2010-03-31 |
$1 |
2009-12-31 |
$4 |
2009-09-30 |
$1 |
2009-06-30 |
$1 |
2009-03-31 |
$1 |
Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|